Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Redhill Biopharma Ltd. (RDHL) vs cbdMD, Inc. (YCBD)

Redhill Biopharma Ltd. and cbdMD, Inc. are both Drug Manufacturers Specialty & Generic companies. cbdMD, Inc. is the larger, with a market value of $4.8M against $3.2M — 1.5× the size. Redhill Biopharma Ltd. has negative trailing earnings, so its P/E is not meaningful; cbdMD, Inc. trades at 55.3×. cbdMD, Inc. grew revenue faster over the last twelve months: 10.0% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −14.7%) and the higher return on invested capital (0.00% vs −29.8%). Across the 16 metrics below, Redhill Biopharma Ltd. leads on 8 and cbdMD, Inc. on 8.

Valuation

Metric RDHL YCBD Drug Manufacturers Specialty & Generic median
P/E n/m 55.29 20.14
P/S 0.32 0.24 2.25
P/B n/m 0.61 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.30 0.26 2.56
Earnings yield (122,133.34%) 1.81% (2.99%)
Free cash flow yield (909.75%) (49.69%) 0.00%

Profitability

Metric RDHL YCBD Drug Manufacturers Specialty & Generic median
Gross margin 35.16% 57.68% 53.94%
Operating margin 0.00% (13.87%) 0.00%
Net margin 25.20% (14.71%) 0.00%
Free cash flow margin 0.00% (11.51%) 0.00%
Return on equity 0.00% (43.01%) (0.40%)
Return on assets 0.00% (26.73%) (3.32%)
Return on invested capital 0.00% (29.78%) 0.00%

Growth

Metric RDHL YCBD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (61.93%) 10.01% 10.01%
EPS growth (last fiscal year) 97.91% 92.39% —
Revenue growth, 5-year CAGR (66.15%) (14.45%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RDHL YCBD Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 0.56 2.50 2.31
Net debt to EBITDA 0.53 6.17 0.85

Dividend

Metric RDHL YCBD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric RDHL YCBD Drug Manufacturers Specialty & Generic median
Market cap 3.22m 4.76m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack